Explore The 2024 Edition of Industry Pages™ — A Strategic Guide To Running Smarter, Faster, And Leaner Studies

The 2024 Industry Pages report by Palleos provides an in-depth examination of the Central and Eastern European (CEE) clinical trial strategy, highlighting its pivotal role in global drug development. Of the 50 novel drugs approved by the U.S. FDA in 2024, 42 included data from trials conducted in CEE countries. Similarly, nearly one-third of new EMA-authorized medicines involved research sites across the region.

This comprehensive analysis explores key factors driving the region’s appeal, including accelerated patient enrollment, strong regulatory alignment with EMA/FDA standards, and consistently high inspection compliance rates. This report profiles leading countries—Germany, Poland, Hungary, Czech Republic, and others—detailing their capabilities in Phase I–IV studies, therapeutic strengths, infrastructure, and regulatory timelines. With the adoption of the EU Clinical Trials Information System (CTIS), the region has entered a more transparent and harmonized regulatory era. The report also documents increasing trial volumes, improved CTA approval speeds, and the strategic use of CEE countries for rescue studies. As R&D complexity grows and enrollment challenges persist globally, Central and Eastern Europe emerges as a vital, cost-effective, and quality-assured partner for biopharma sponsors aiming to accelerate clinical development.